Tegretol Retard

Quick links

Choose a section

Quick links to important sections

Advertisements

Tegretol Retard

Advertisements

Overview of Tegretol Retard

Quick Facts

Property Description
Active ingredient Carbamazepine
Form Prolonged-release oral tablets
Pharmacological class Anticonvulsant, Mood stabilizer
Common purpose Stabilizing nerve membranes
Origin Synthetic, Dibenzoazepine derivative

1. Identity, Classification, and Composition of Tegretol Retard

Tegretol Retard is a prescription-only medicine containing the sole active ingredient, Carbamazepine, a synthetic chemical entity belonging to the Dibenzoazepine derivative group. Its pharmacological classification is primarily as an Anticonvulsant or Antiepileptic Drug (AED), a class used for managing electrical stability in the nervous system.

Beyond its core antiepileptic role, Carbamazepine is also clinically recognized for its properties as a Mood stabilizer and an Antineuralgic agent. This dual classification reflects its ability to stabilize pathologically hyperexcitable nerve membranes, a key differentiator among many central nervous system therapies.


2. What Does 'Retard' Mean in the Drug's Formulation?

The designation 'Retard' signifies that the medicine is a specialized modified-release dosage form, delivered as a prolonged-release oral tablet. This sustained-release formulation is engineered for oral administration to release Carbamazepine slowly and consistently over an extended duration.

This long-acting mechanism is a critical pharmaceutical feature that differs from conventional, immediate-release tablets. The purpose of this design is to maintain more stable, uniform drug concentrations in the bloodstream, helping to avoid the sharp fluctuations associated with standard forms.


3. What is the General Purpose of Anticonvulsant Therapy?

The general purpose of a medication classified as an Anticonvulsant is to restore balance and stability to the nervous system by regulating excessive electrical signaling in nerve cells. The essential action involves stabilizing hyperexcitable nerve membranes by blocking voltage-gated sodium channels.

By controlling the rapid flow of ions necessary for transmitting impulses, the medicine acts to reduce overall nerve cell excitability. This dampening effect on erratic signaling is the fundamental goal of the therapy, supporting a more consistent function of the central nervous system.

Regulatory References

  1. NIH StatPearls: Carbamazepine
  2. MedlinePlus: Carbamazepine Drug Information
Advertisements

What side effects are possible with Tegretol Retard?

Possible side effects and safety information

Official regulatory documents characterize the safety profile of Carbamazepine by classifying potential adverse reactions according to frequency and affected physiological system. The most common effects are primarily categorized as Nervous System disorders and Gastrointestinal disturbances.

Very Common reactions (occurring in 1 in 10 or more people) include dizziness, somnolence, ataxia (uncoordinated movement), nausea, and vomiting. Common reactions (occurring in less than 1 in 10 but more than 1 in 100 people) often involve temporary changes in blood counts, such as leukopenia and thrombocytopenia, along with hyponatremia (low sodium levels).


Serious Adverse Reactions and Key Safety Constraints

The medicine is associated with the potential for rare, but clinically significant, Serious Adverse Reactions. These include severe cutaneous reactions, such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), which are most likely to appear in the first few months of treatment. Fatal hematologic events, specifically Aplastic Anaemia and Agranulocytosis, are also explicitly documented in official labeling.

Safety notes for specific populations include genetic warnings: the *HLA-B1502 allele is associated with an increased risk of SJS/TEN in certain populations, particularly those of Asian ancestry. Use of the medicine is restricted or contraindicated in individuals with a history of bone marrow depression or known sensitivity to tricyclic compounds**. The labeling notes that caution is needed in older adults due to the potential for drug interactions.

Advertisements

Overdose and Emergency Response

Overdose Map: Overdose and When to Seek Help — Official Regulatory Information for Tegretol Retard

Overdose scope Entity/Statement (Strictly Regulatory)
Documented overdose presentations: Symptoms of Central Nervous System (CNS) depression (drowsiness, stupor, coma), ataxia, nystagmus, and seizures [FDA, EMA].
Physiological systems affected (as stated in label): Cardiovascular (Cardiac arrest, conduction disturbances); Respiratory (Respiratory depression); Metabolic (Hyponatremia) [EMA, FDA].
Dose-related or exposure-related factors (if applicable): Risk of Serotonin syndrome with concomitant use of certain other medicines [FDA].
Population-specific overdose notes (if applicable): Rapid progression to coma and seizures in young children; potential for more severe overdose in elderly patients [EMA].
Emergency-response statements (as written in official documents): Symptomatic and supportive treatment; Procedures may include Gastric emptying/Lavage and Activated charcoal [FDA, EMA].
When immediate medical help is required (label-derived phrasing only): Seek immediate medical attention and Contact emergency services immediately [FDA, EMA].

Overdose Classifications (High-Level)

Classification Description (Strictly Regulatory)
Severity classification (as defined in official documents): Potential for severe and life-threatening overdose.
Regulatory basis (EMA / FDA / etc.): Information derived from FDA Prescribing Information and EMA/National Medicines Authority SmPC.
Overdose-context constraints (as defined in official documents): No specific antidote is known. Hospital monitoring is required for observation of vital functions [FDA, EMA].

Resulting Overdose Structure

Official overdose statements:

  • Regulator-mandated action requires individuals to seek immediate medical attention due to the documented risk of severe outcomes.
  • Manifestations include profound CNS depression leading to coma, along with life-threatening cardiac conduction disturbances and respiratory depression.
  • Management is limited to symptomatic and supportive treatment, including the use of activated charcoal and strict hospital monitoring of vital signs, as no specific antidote is known.

Connection to the overall overdose profile (2–4 sentences): The official regulatory documents define the Carbamazepine overdose profile by detailing specific, severe physiological failures, primarily affecting the central nervous and cardiovascular systems. This inherent risk level dictates the explicit instruction for immediate medical attention to allow for required supportive care and continuous observation in a medical facility.

Advertisements

Therapeutic Uses of Tegretol Retard

The therapeutic utility of Tegretol Retard (Carbamazepine) is applied across domains where additional symptomatic support is needed, primarily focusing on conditions involving heightened physiological activity. The medicine is commonly used to help with symptoms related to acute or episodic changes across three main therapeutic areas. This medication is applied in clinical settings that involve acute or unstable symptom patterns. Its established uses include managing specific seizure patterns (such as partial and generalized tonic-clonic types), stabilizing acute manic episodes in Bipolar I Disorder, and relieving severe neuropathic pain, particularly trigeminal neuralgia. The drug is relevant in conditions characterized by periods of heightened symptoms, which may assist with maintaining functional stability and contributing to easing the overall symptom load.


Quick Fact: Relief for Neurological Disruption

Domain of Use Core Symptom Management Patient Benefit
Epileptology Symptoms of increased neurological activity Supports functional stability
Psychiatry Symptoms related to systemic imbalance Contributes to easing symptom load
Neurology Symptoms related to physical discomfort Provides supportive relief
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Tegretol Retard?

The eligibility for Tegretol Retard (Carbamazepine) is strictly defined by regulatory authorities based on pre-existing conditions, genetic factors, and age.

Population Status Restrictions and Prohibitions
Contraindicated Prohibited in patients with a history of bone marrow depression or hepatic porphyrias. Absolute prohibition applies to individuals with known hypersensitivity to Carbamazepine or related tricyclic compounds, and those taking Monoamine Oxidase Inhibitors (MAOIs).
Conditional Use Mandatory genetic screening for the *HLA-B1502 allele is required for at-risk Asian populations. Caution is required in patients with pre-existing cardiac conduction issues or hepatic dysfunction**.
Age-Related Approved for use in adults and children 4 years and older for specific seizure types. Use in children under 6 requires strict individualized determination.
Reproductive Status Use during pregnancy is restricted due to the potential for fetal harm; effective contraception must be used by women of childbearing potential.

Official regulatory documents strictly define patient suitability by classifying populations as contraindicated, restricted, or permitted with caution, based exclusively on established risk data.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Carbamazepine (the active ingredient in Tegretol Retard) is complex and defined by its role as a potent enzyme and transporter modifier, as documented by regulatory agencies.

Contraindicated and Restricted Combinations

Co-administration with Nefazodone and Delavirdine is formally contraindicated by regulatory labeling. Furthermore, Monoamine Oxidase Inhibitors (MAOIs) are not recommended and require a mandatory separation period: they must be discontinued for a minimum of 14 days prior to initiating Carbamazepine therapy.

Pharmacokinetic Interactions

Carbamazepine is a strong inducer of the CYP3A4 enzyme and P-glycoprotein (P-gp). This interaction accelerates the metabolism of many co-administered medicines, resulting in their decreased plasma concentrations. Affected product classes include Direct Oral Anticoagulants, Hormonal Contraceptives, and certain Antipsychotics and Corticosteroids.

Conversely, co-administration with strong CYP3A4 inhibitors, such as certain Macrolide Antibiotics (e.g., Erythromycin) and Azole Antifungals, formally results in increased plasma concentrations of Carbamazepine itself.

Other Documented Interactions

Specific non-medicinal substances, including Grapefruit Juice and the herbal product St John's Wort, are officially documented to modify systemic exposure. Concurrent use of Alcohol (Ethanol) may result in additive Central Nervous System (CNS) depression.

Advertisements

Mechanism of Action

The mechanism of action for Tegretol Retard (Carbamazepine) is rooted in modulating nerve membrane potential within the central nervous system (CNS). The primary target is the Voltage-Gated Sodium Channel (VGSC). Carbamazepine and its active metabolite, carbamazepine-10,11-epoxide, function as inhibitors that preferentially bind to the inactivated state of the VGSC. This use-dependent interaction prolongs the channel's inactivation, restricting the rapid flux of sodium ions. This molecular cascade results in the suppression of high-frequency repetitive neuronal firing.

The inhibition of rapid discharge decreases the propagation of electrical signals and limits polysynaptic responses and post-tetanic potentiation, which amplify nerve signaling. The resulting physiological consequence is the reduction of generalized neural hyperexcitability within CNS pathways. Secondary modulation also occurs in the central chemical signaling pathways, influencing inhibitory GABA signaling and modulating the release of the excitatory neurotransmitter Glutamate, which further influences the reduction of overall neural excitability. The prolonged-release formulation facilitates sustained VGSC inhibition by supporting stable target occupancy over time.

Advertisements

Dosage and Administration Information

How to Use Tegretol Retard (Carbamazepine Extended-Release) — Administration Guidelines

This information describes the instructions for the use of Tegretol Retard tablets, which is an extended-release formulation of carbamazepine.


Core Administration Scope

Instruction Specification
Route of Administration Oral (by mouth)
Frequency Twice Daily (approximately every 12 hours)
Intake Condition Should generally be taken with a meal

Procedural Instructions and Constraints

Tablet Integrity: The extended-release tablets must be swallowed whole with a glass of liquid. To maintain the controlled-release mechanism, the tablets must not be crushed, chewed, or split before swallowing.

Dosing Schedule: Treatment must be initiated with a low starting dose and gradually titrated (increased slowly) over several weeks to reach the optimal maintenance dose. For adults, the initial dose is typically 200 mg taken twice daily, with subsequent adjustments made incrementally under a healthcare professional's guidance. The recommended maintenance dosage for adults with epilepsy typically ranges from 800 mg to 1200 mg daily.

Age-Specific Use: Dosing for children and adolescents is determined by specific guidelines, often based on age and weight, and must adhere to the established initial and maximum daily dose limits.

Missed Dose: If a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose must be skipped, and the regular schedule resumed. The dose must not be doubled.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of Studies for Tegretol Retard

Evidence for Use in Epilepsy (Partial and Generalized Tonic-Clonic Seizures)

Carbamazepine has been evaluated in numerous studies for specific types of seizures. The research base is founded on numerous Randomized Controlled Trials (RCTs) and comprehensive Meta-analyses. These studies explored how symptoms change over time, comparing the medicine against other anti-seizure medications and using it as a reference point for newer treatments.

Researchers monitored outcomes such as the Seizure Freedom Rate (SFR)—measuring the number of people who reported being seizure-free over defined periods—and the Retention Rate (RR)—monitoring the proportion of people who remained on the treatment. The research landscape for this condition is well-documented, but certain limitations exist. Data show patterns related to patient discontinuation, and evidence suggests that tolerability issues may be associated with earlier treatment withdrawal.


Evidence for Use in Acute Manic and Mixed Episodes in Bipolar I Disorder

Research explored Carbamazepine in studies focusing on acute episodes where symptoms become more noticeable as part of Bipolar I Disorder. The framework includes Randomized Controlled Trials comparing the medicine against an inactive placebo, as well as trials comparing it to other known mood stabilizers.

Studies described the changes measured in manic symptoms using clinical rating scales like the Young Mania Rating Scale (YMRS). The most controlled evidence for this use is often derived from trials lasting only a few weeks, which provides insight into short-term changes but offers limited information about intermediate-term stabilization. Findings were mixed when comparing the medicine directly against some other long-established mood stabilizers in certain study populations.


Long-Term Studies and What Remains Uncertain

For all indications, the evidence regarding long-term outcomes is not fully established through extensive, blinded, controlled trials. Data for follow-up over many years often comes from observational data or open-label extensions of the initial trials.

Long-term patterns and the durability of research findings are not always certain. Research provides context but not individual predictions about whether the observed patterns are durable. A key limitation is that the results apply only to the populations studied, and data for certain special groups, such as children and adolescents, remain insufficient.

Key Studies & References

  1. Carbamazepine in the acute treatment of bipolar disorder: a systematic review of the literature and proposed treatment guidelines
  2. Epilepsies: diagnosis and management - NICE Guideline [CG137]
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Tegretol Retard (FAQ)

Q: What are the main uses of Tegretol Retard besides epilepsy?

A: According to official product information, the active ingredient in Tegretol Retard is also indicated for treating a specific type of nerve pain called Trigeminal Neuralgia. It is also used in the treatment of acute manic and mixed episodes associated with Bipolar I Disorder, where it acts as a mood stabilizer.

Q: Is Tegretol Retard used for nerve pain like trigeminal neuralgia?

A: Yes, regulatory documents indicate that carbamazepine, the active ingredient, is specifically approved for use as an analgesic (pain reliever) to treat Trigeminal Neuralgia. This is one of the primary, non-epilepsy indications for the medication.

Q: Can children or pediatric patients use Tegretol Retard?

A: Official labeling confirms that the medication is approved for use in children for certain seizure types, typically in those 4 years of age and older. Dosing for children and adolescents is specialized and is typically determined by a healthcare professional.

Q: What kind of research supports the use of Tegretol Retard for bipolar disorder?

A: Studies and official information indicate that controlled trials have demonstrated the medication's effectiveness in reducing the symptoms of manic episodes associated with Bipolar I Disorder. The research involves measuring changes in these symptoms compared to placebo or other treatments.

Q: Is it possible for Tegretol Retard to cause hair loss?

A: Hair loss is not typically listed among the most common adverse reactions. However, official post-marketing data reports that it has occurred as a rare or uncommon side effect of the active ingredient, carbamazepine, in some patients.

Q: What are the long-term side effects of Tegretol Retard?

A: Regulatory documents mention the potential for effects on the body over time, notably including bone metabolism, which may lead to reduced bone mineral density. Official guidelines note the importance of ongoing monitoring of blood and liver function, particularly during long-term therapy.

Q: Do I need to get blood tests while on Tegretol Retard?

A: Official labeling states that frequent laboratory supervision is necessary throughout treatment. This monitoring is performed to check for potential blood disorders and other changes in blood cell counts.

Q: What is the connection between Tegretol Retard and sodium levels?

A: Official information lists Hyponatremia (low sodium levels in the blood) as a Common adverse reaction. Official documentation notes that patients with certain predisposing medical conditions may have an increased risk.

Q: Why do doctors often start with a low dose of Tegretol Retard?

A: Official instructions mandate that treatment must begin with a low initial dose and then be gradually increased over time (titrated). This approach is generally used to allow the body to adjust to the medication, which may help improve overall tolerability.

Q: What should I do if the side effects of Tegretol Retard don't go away?

A: Official labeling states that contact with a healthcare provider is important if serious reactions, such as a severe rash or fever, appear. Guidance from a healthcare professional should also be sought if side effects, even common ones, persist or change.

Q: Can Tegretol Retard cause skin issues or a rash?

A: Yes, skin reactions are a known risk. These range from common rashes to rare, but potentially fatal conditions like Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). These severe reactions are most likely to occur in the first few months of treatment.

Q: Can men taking Tegretol Retard experience fertility issues?

A: Official labeling contains a section acknowledging the potential reproductive risks for males. Specifically, it notes that the active ingredient in this medication may impair fertility in men of reproductive potential.

Q: Does Tegretol Retard cause weight gain in most people?

A: Official documents indicate that weight gain is a potential adverse reaction to carbamazepine. However, it is generally listed as less frequent than other side effects like dizziness or drowsiness.

Q: Are dizziness and tiredness common side effects when starting Tegretol Retard?

A: Dizziness and Somnolence (drowsiness or tiredness) are classified as Very Common adverse reactions in regulatory documents. This suggests they are frequently experienced by patients, often during the initial phase of treatment.

Q: Can Tegretol Retard affect my sleep?

A: Yes, official labeling lists somnolence (drowsiness or sleepiness) as a Very Common side effect. Since this can affect a person's state of alertness during the day, it may also impact overall sleep patterns.

Q: What happens if I miss a dose of Tegretol Retard?

A: Missing a dose can cause the level of the medication in the blood to drop, which official guidance warns against. The extended-release formulation is designed to maintain steady blood levels. Specific instructions on handling a missed dose are outlined in the product information.

Q: Can I drink coffee while taking Tegretol Retard?

A: Caffeine is not explicitly listed as a prohibited interaction. However, because the medication commonly causes somnolence (drowsiness), patients should discuss with their healthcare provider the use of substances that affect the central nervous system.

Q: Is it safe to take Tegretol Retard with pain relievers like ibuprofen?

A: Some regulatory documents have noted that non-prescription pain relievers, such as ibuprofen, may inhibit the metabolism of the active ingredient's chemical breakdown product. This could potentially lead to higher levels of the medication. Any changes to medication use should involve professional guidance.

Q: Will taking Tegretol Retard affect my driving ability?

A: Yes, official labeling explicitly warns that the medication can impair the ability to perform tasks requiring high alertness, such as driving or operating machinery. This is due to common adverse reactions like dizziness, somnolence, and lack of coordination.

Q: How long does Tegretol Retard stay in your system?

A: The time it takes for the medication to be eliminated from the body varies. The initial half-life shortens with repeated use because the drug encourages its own breakdown. This means that a significant portion of the medication leaves the system within a day or less after multiple doses.

Q: Are there any dietary restrictions when taking Tegretol Retard?

A: Yes, the co-consumption of Grapefruit Juice is explicitly documented in official sources as an interaction. Grapefruit juice can increase the systemic exposure of the drug, and its use is generally discouraged.

Q: Does Tegretol Retard cause memory problems or difficulty concentrating?

A: Official warnings note the potential for the medication to impair functions such as judgment, thinking, and motor skills. Adverse reactions related to disturbances in attention and reduced concentration have also been reported.

Q: Can taking Tegretol Retard make me more sensitive to the sun?

A: Official documents report that photosensitivity reactions (increased skin sensitivity to sunlight) have occurred with the use of carbamazepine. These reactions are typically classified as uncommon or rare side effects.

Q: What if I need to take a cold or flu medicine while on Tegretol Retard?

A: Many over-the-counter cold and flu preparations contain ingredients that can interact with Tegretol Retard. Specifically, some ingredients may increase the risk of additive Central Nervous System (CNS) depressant effects like drowsiness. Any co-administration of medicine should be discussed with a healthcare provider.

Q: Are there any vitamins or supplements that interact with Tegretol Retard?

A: Yes, the herbal supplement St John's Wort is specifically documented in regulatory sources to interact with the medication. Also, due to the drug's effect on bone health, some official bodies recommend considering Vitamin D supplementation.

Q: Is anxiety a known side effect of Tegretol Retard?

A: While anxiety is not always listed as a common side effect, official warnings note the potential for a range of psychiatric adverse reactions, including the emergence or worsening of suicidal thoughts and behavior. Any changes in mood are important to bring to the attention of a healthcare provider.

Q: What is the risk of drug-induced liver injury with Tegretol Retard?

A: The medication is associated with a risk of hepatic dysfunction (liver issues). This includes rare reports of hepatitis and jaundice. Due to this risk, regulatory authorities note the importance of monitoring liver function.

Q: Does the medication need to be tapered off when stopping Tegretol Retard?

A: Official labeling advises that the medication should not be stopped suddenly. Abrupt discontinuation should be avoided as it can increase the risk of seizures and is associated with potential withdrawal effects. Discontinuation is typically managed through a gradual process.

Q: Can Tegretol Retard cause changes in vision?

A: Yes, changes in vision are listed as potential adverse reactions, particularly when treatment is initiated or if higher doses are taken. These changes include blurred vision and diplopia (seeing double).

Q: Does Tegretol Retard have a mood-lifting effect?

A: The medication is officially classified as a mood stabilizer and is indicated for treating manic and mixed episodes in Bipolar I Disorder. Its primary action is to stabilize mood and reduce extreme hyperexcitability, not necessarily to create a mood-lifting effect.

Q: What studies have been done on the safety of Tegretol Retard in long-term use?

A: The official research base includes observational data and extensions of the original trials to track long-term safety. While extensive, multi-year, blinded controlled trials are noted as being limited, this evidence is used to establish guidance for long-term monitoring.

Q: Is it common for people to switch from immediate-release Tegretol to Tegretol Retard?

A: Official labeling provides specific guidance regarding the transition, or conversion, of patients from the immediate-release formulation to the extended-release (Retard) tablets. This confirms that it is a recognized and standard administrative transition.

Q: Can Tegretol Retard change my personality or mood significantly?

A: The active ingredient has the potential to cause psychiatric adverse reactions. Official warnings highlight the risk of the emergence or worsening of suicidal thoughts and behavior or other significant mood alterations. Any change in mood or behavior is important to bring to the attention of a healthcare provider.

Q: Is Tegretol Retard addictive?

A: Official regulatory documents typically classify this medication as having no known potential for physical dependence or abuse. It is not considered an addictive substance.

Advertisements

How should Tegretol Retard be stored and disposed of?

How to Store and Dispose of Tegretol Retard

Official regulatory documents define strict conditions for the storage and disposal of Tegretol Retard (carbamazepine prolonged-release tablets) to maintain product integrity and safety.

Storage Requirements

  • Temperature: Store the medication at room temperature, specifically between 15°C and 30°C (59°F and 86°F).
  • Protection: The product must be protected from moisture/humidity and the container should be kept tightly closed.
  • Child Safety: It is mandatory that the medicine be kept out of the reach and sight of children.

Disposal Instructions

Disposal of unused or expired tablets must be completed in accordance with all local, regional, national, and international regulations. The preferred method is to use a drug take-back program. If one is unavailable, the tablets should be mixed with an undesirable substance, placed in a sealed container, and thrown into the household trash, not flushed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tegretol Retard found in:

A-Z Index: